MARKET

DHR

DHR

Danaher
NYSE

Real-time Quotes | Nasdaq Last Sale

227.03
+3.20
+1.43%
After Hours: 227.03 0 0.00% 16:41 10/20 EDT
OPEN
224.01
PREV CLOSE
223.83
HIGH
229.00
LOW
223.56
VOLUME
2.30M
TURNOVER
--
52 WEEK HIGH
229.45
52 WEEK LOW
119.60
MARKET CAP
161.06B
P/E (TTM)
58.46
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
ITT vs. DHR: Which Stock Is the Better Value Option?
ITT vs. DHR: Which Stock Is the Better Value Option?
Zacks · 6h ago
Were Hedge Funds Right About Crowding Danaher Corporation (DHR)?
With this in mind let’s see whether Danaher Corporation (NYSE:DHR) makes for a good investment at the moment. We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data […]
Insider Monkey · 6h ago
Cramer's lightning round: 'I'd rather own Snowflake than I would Cloudera'
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
CNBC.com · 23h ago
The Zacks Analyst Blog Highlights: PPG, PG, Philip Morris, Northrop and Danaher
The Zacks Analyst Blog Highlights: PPG, PG, Philip Morris, Northrop and Danaher
Zacks · 1d ago
Danaher (DHR) to Report Q3 Earnings: Is a Beat in Store?
Danaher's (DHR) Q3 results are expected to reflect a healthy demand for products in Life Sciences and Diagnostics segments. Also, Cytiva is anticipated to have aided core sales.
Zacks · 1d ago
When Should You Buy Danaher Corporation (NYSE:DHR)?
Simply Wall St. · 3d ago
Moody's Outlook for the US medical products and devices industry revised to positive on higher earnings, increased demand
Moody's · 3d ago
Cooper Investors Global Equities Fund (Hedged) Quarterly Commentary Report - September 2020
Cooper Investors Pty Limited ("CI") is a specialist equities fund manager with funds under management of approximately A$13 billion.The portfolio returned 9.18% for the quarter versus 6.94% for the benchmark. Over a rolling 12 months the portfolio has returned 8.74% while the benchmark has returned 9.05%.The biggest contributors to outperformance in the quarter were Danaher (stronger than expected earnings), Techtronic (results for the half-year significantly better than peer group and market expectations), and TSMC (continued strong trends including potential outsourcing by Intel for 7-nanometer chips).In the midst of the technology pull back in September the Fund bought a position in Paycom, a leading Software-as-a-Service [‘SAAS’] provider of payroll and human capital management [‘HCM’] solutions in the US.
Seekingalpha · 4d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DHR. Analyze the recent business situations of Danaher through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DHR stock price target is 224.67 with a high estimate of 250.00 and a low estimate of 205.00.
EPS
Institutional Holdings
Institutions: 1.51K
Institutional Holdings: 589.90M
% Owned: 83.15%
Shares Outstanding: 709.41M
TypeInstitutionsShares
Increased
434
21.03M
New
107
2.95M
Decreased
604
19.47M
Sold Out
60
2.57M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.47%
Healthcare Equipment & Supplies
+0.08%
Key Executives
Chairman/Director
Steven Rales
President/Chief Executive Officer/Director
Rainer Blair
Chief Financial Officer/Executive Vice President
Matthew McGrew
Executive Vice President
Daniel Comas
Executive Vice President
Joakim Weidemanis
Senior Vice President/Chief Accounting Officer
Robert Lutz
Senior Vice President/Chief Compliance Officer/General Counsel
Brian Ellis
Senior Vice President/Director of Human Resources
Angela Lalor
Senior Vice President
William King
Senior Vice President
Daniel Raskas
Lead Director/Independent Director
Linda Hefner Filler
Director
Mitchell Rales
Independent Director
Teri List-Stoll
Independent Director
Walter Lohr
Independent Director
Jessica Mega
Independent Director
Walter Lohr,
Independent Director
Pardis Sabeti
Independent Director
John Schwieters
Independent Director
Alan Spoon
Independent Director
Raymond Stevens
Independent Director
Elias Zerhouni
Independent Director
Elias Zerhouni,
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
09/15/2020
Dividend USD 0.18
09/25/2020
05/05/2020
Dividend USD 0.18
06/25/2020
02/20/2020
Dividend USD 0.18
03/26/2020
12/10/2019
Dividend USD 0.17
12/26/2019
09/10/2019
Dividend USD 0.17
09/26/2019
05/07/2019
Dividend USD 0.17
06/27/2019
03/08/2019
Dividend USD 0.17
03/28/2019
12/03/2018
Dividend USD 0.16
12/27/2018
09/11/2018
Dividend USD 0.16
09/27/2018
05/08/2018
Dividend USD 0.16
06/28/2018
02/20/2018
Dividend USD 0.16
03/28/2018
12/05/2017
Dividend USD 0.14
12/28/2017
09/12/2017
Dividend USD 0.14
09/28/2017
05/10/2017
Dividend USD 0.14
06/28/2017
02/22/2017
Dividend USD 0.14
03/29/2017
12/07/2016
Dividend USD 0.125
12/28/2016
09/14/2016
Dividend USD 0.125
09/28/2016
05/11/2016
Dividend USD 0.16
06/01/2016
03/02/2016
Dividend USD 0.16
03/22/2016
12/09/2015
Dividend USD 0.135
12/17/2015
09/21/2015
Dividend USD 0.135
09/30/2015
05/18/2015
Dividend USD 0.135
06/24/2015
02/25/2015
Dividend USD 0.135
03/25/2015
12/10/2014
Dividend USD 0.1
12/23/2014
09/09/2014
Dividend USD 0.1
09/24/2014
05/07/2014
Dividend USD 0.1
06/25/2014
02/19/2014
Dividend USD 0.1
03/26/2014
12/11/2013
Dividend USD 0.025
12/26/2013
09/12/2013
Dividend USD 0.025
09/25/2013
05/23/2013
Dividend USD 0.025
06/26/2013
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About DHR
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through three segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification. Danaher's research and development, manufacturing, sales, distribution, service and administrative facilities were located in over 60 countries.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Danaher Corporation stock information, including NYSE:DHR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DHR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DHR stock methods without spending real money on the virtual paper trading platform.